Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
72 participants
INTERVENTIONAL
2018-06-25
2021-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salmeterol Effect on Exercise Performance
NCT06655012
cAMP Signaling and Muscle Adaptations
NCT02557581
Physiological Response to Salbutamol and Exercise
NCT03902106
The Effect of High Dose Salbutamol on Muscle Performance
NCT01415596
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.
NCT04757532
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Subjects receive placebo treatment
Placebo
Subjects are treated with placebo
Long acting beta2-agonist
Subjects are treated with long-acting beta2-agonist formoterol
Formoterol
Subjects are treated with daily inhalation of formoterol
Short acting beta2-agonist
Subjects are treated with short-acting beta2-agonist terbutaline
Terbutaline
Subjects are treated with daily inhalation of terbutaline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Formoterol
Subjects are treated with daily inhalation of formoterol
Terbutaline
Subjects are treated with daily inhalation of terbutaline
Placebo
Subjects are treated with placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* VO2max \>55 ml/kg/min for men and \>50 ml/kg/min for women (± biologic and techinical variation of 5.6% (Katch et al. 1982)
* Body Mass Index (BMI) \< 26
Exclusion Criteria
* Serious adverse side effects of the used study drug
* Chronic disease that by the project physician would affect any of the outcomes of the study
* Smoker
* Chronic use of prescription medication (other than contraceptives for women)
* Pregnancy
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Morten Hostrup, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FOR/TER
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.